Pathologic Complete Response to Neoadjuvant FOLFOX in Combination with Bevacizumab in Unresectable Metastatic Colorectal Carcinoma

A 32-year-old Asian male presented with perforated sigmoid colorectal cancer (CRC) and large, unresectable hepatic metastasis. After surgery for his primary tumor, he received 6 months of FOLFOX (5-fl uorouracil/leucovorin/oxaliplatin) plus bevacizumab and achieved a partial response. He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment. The literature regarding pCR with chemotherapy in CRC and the implications for further management is discussed herein.